SCHEMBL9192069

SCHEMBL9192069

Cc1cccc(NC(=O)Nc2cccnc2)c1

nearest known ligand 0.72

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 7/20 0.72
NPC1 O15118 3/20 0.72
RAB9A P51151 3/20 0.72
PKM P14618 1/20 0.72
SMN1; SMN2 Q16637 1/20 0.72
ALDH1A1 P00352 2/20 0.71
HTT P42858 2/20 0.71
GAA P10253 2/20 0.70
TAAR1 Q96RJ0 1/20 0.68
IMPDH2 P12268 2/20 0.68
MEN1 O00255 6/20 0.68
MAPT P10636 3/20 0.68
LMNA P02545 3/20 0.68
ATM Q13315 1/20 0.68
BRAF P15056 1/20 0.60
KDM4E B2RXH2 1/20 0.58
TP53 P04637 1/20 0.58
CYP1A2 P05177 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL9187992 0.98 KMT2A (0.70) KMT2ANPC1RAB9APKMSMN1; SMN2
SCHEMBL9637653 0.85 MEN1 (0.77) KMT2ANPC1RAB9APKMALDH1A1
SCHEMBL30051982 0.85 MEN1 (0.77) KMT2ANPC1RAB9APKMALDH1A1
SCHEMBL4416620 0.85 SMN1; SMN2 (0.77) KMT2ANPC1RAB9APKMSMN1; SMN2
SCHEMBL29703055 0.85 SMN1; SMN2 (0.77) KMT2ANPC1RAB9APKMSMN1; SMN2
SCHEMBL5853939 0.84 RAB9A (1.00) KMT2ANPC1RAB9APKMALDH1A1
SCHEMBL30354462 0.84 RAB9A (1.00) KMT2ANPC1RAB9APKMALDH1A1
SCHEMBL5187554 0.84 SMN1; SMN2 (0.71) KMT2ANPC1RAB9APKMSMN1; SMN2
Hydrochloric Acid SCHEMBL29388210 0.83 MEN1 (0.74) KMT2ANPC1RAB9APKMALDH1A1
Bromide SCHEMBL29417998 0.83 MEN1 (0.74) KMT2ANPC1RAB9APKMALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0682656-A1 USE OF PHENYL HETEROARYL UREAS AS 5HT 2C? RECEPTOR ANTAGONISTS AND UREA COMPOUNDS SMITHKLINE BEECHAM PLC (GB) 1995-11-22 EP claimed
WO-1994018170-A1 USE OF PHENYL HETEROARYL UREAS AS 5HT2C RECEPTOR ANTAGONISTS AND UREA COMPOUNDS SMITHKLINE BEECHAM PLC (GB) 1994-08-18 WO claimed
US-20210022340-A1 USE OF PYRIDINE UREA COMPOUND HAVING SNAIL-KILLING ACTIVITY THE NATIONAL INSTITUTE OF PARASITIC DISEASES, CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION (CN) 2021-01-28 US disclosed
US-10556898-B2 Indazolyl-1,2,4-thiadiazolamines and related compounds for inhibition of Rho-associated protein kinase and the treatment of disease LYCERA CORPORATION (US) 2020-02-11 US disclosed
US-20190276447-A1 INDAZOLYL-1,2,4-THIADIAZOLAMINES AND RELATED COMPOUNDS FOR INHIBITION OF RHO-ASSOCIATED PROTEIN KINASE AND THE TREATMENT OF DISEASE LYCERA CORPORATION 2019-09-12 US disclosed
EP-0682656-A1 USE OF PHENYL HETEROARYL UREAS AS 5HT 2C? RECEPTOR ANTAGONISTS AND UREA COMPOUNDS SMITHKLINE BEECHAM PLC (GB) 1995-11-22 EP disclosed
WO-1994018170-A1 USE OF PHENYL HETEROARYL UREAS AS 5HT2C RECEPTOR ANTAGONISTS AND UREA COMPOUNDS SMITHKLINE BEECHAM PLC (GB) 1994-08-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190276447-A1 INDAZOLYL-1,2,4-THIADIAZOLAMINES AND RELATED COMPOUNDS FOR INHIBITION OF RHO-ASSOCIATED PROTEIN KINASE AND THE TREATMENT OF DISEASE ROCK1, ROCK2, TNK2 KMT2A 1854/4885NPC1 1039/4885RAB9A 635/4885
US-20210022340-A1 USE OF PYRIDINE UREA COMPOUND HAVING SNAIL-KILLING ACTIVITY SLC14A1, UACA, UROD KMT2A 4029/4885NPC1 1905/4885RAB9A 1093/4885
US-10556898-B2 Indazolyl-1,2,4-thiadiazolamines and related compounds for inhibition of Rho-associated protein kinase and the treatment of disease ROCK1, ROCK2, TNK2 KMT2A 1854/4885NPC1 1039/4885RAB9A 635/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.